Source: DRAP compliance notice, 8 October 2026 · Research date: 11 October 2026. Analysis is general information and should be read with the full instrument and subsequent amendments.
DRAP’s notifications list a compliance notice dated 8 October 2026 concerning two-dimensional barcoding and serialisation for manufactured and imported pharmaceutical products, effective 9 October 2026.
Regulatory development and scope
DRAP’s notifications list a compliance notice dated 8 October 2026 concerning two-dimensional barcoding and serialisation for manufactured and imported pharmaceutical products, effective 9 October 2026.
This briefing concerns Drug Regulatory Authority of Pakistan (DRAP), operating in Pakistan. The distinction between statutory instruments, administrative notices, consultations and individual decisions is material: their addressees, commencement and effects should not be treated as identical.
Legal and commercial assessment
Manufacturers, importers and distributors should obtain the full document, confirm product scope and exceptions and review serialization, labelling, stock-transition and traceability procedures.
The affected business must identify the enabling enactment, any relevant delegated legislation, the precise instrument or case, and the scope of the decision. In the healthcare, food & safety field, the recurring legal considerations include product registration, professional licensing, inspection, traceability, safety labelling and advertising claims. A headline or publication-list entry cannot itself establish every condition or effective date.
Who should respond and how
Organisations exposed to the functions of Drug Regulatory Authority of Pakistan should first determine whether they are within the jurisdiction, activity and entity classes actually governed by the development. Any deadline, exemption, permission or right of representation should be verified against the linked document.
The immediate documentary review should concentrate on facility licences, registrations, batch or inspection records and approved product documentation. Businesses should record responsibility for the response, identify any live notices or proceedings and retain the source materials consulted as evidence of compliance diligence.
Status and next verification
Official source reference: DRAP compliance notice, 8 October 2026. Legal status: Compliance notification.
Further circulars, amendments, appeal outcomes or commencement notifications may qualify the original publication. Where the item is an individual enforcement or sector-information release, it should not be described as a universal change in the law.
What should affected organisations do?
Manufacturers, importers and distributors should obtain the full document, confirm product scope and exceptions and review serialization, labelling, stock-transition and traceability procedures.
Recommended action checklist
- Retrieve the signed or notified source and verify the applicable provisions and effective dates.
- Determine the entity classes, operations and transactions within the instrument’s scope.
- Document the required internal action and responsibility, including any filing, approval or response deadline.
- Check for later amendments, appeal outcomes or clarifying instructions before relying on the initial publication.
Timing and legal status
Published or listed 2026-10-08. Check instrument-specific commencement, conditions and subsequent notices.
This source-based analysis does not establish conditions absent from the complete original instrument. Confirm its current status.
Drug Regulatory Authority of Pakistan — original official source listing